FIREBRICK PHARMA LIMITED — Share Issue/Capital Change 2026

May 19, 2026

FirebrickPharma

20 May 2026

ASX Announcement

Close of Offer – Listing Options

Firebrick Pharma Limited (ASX:FRE) (Firebrick, Company) advises that the Offer for Listing Options has closed with no further Options being issued (see ASX announcement 15 May).

The ASX has granted quotation of the previously issued Options with an exercise price of $0.095 (9.5 cents) expiring 4 July 2028 under ASX Code “FREO”.

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman of Firebrick Pharma Limited.

• ENDS -

About Firebrick (ASX:FRE)

Firebrick Pharma is developing and commercialising novel formulations and uses of povidone-iodine (PVP-I). Its first product, Nasodine® Nasal Spray (0.5% PVP-I), has been introduced into the United States, Singapore, and Fiji & South Pacific. Nasodine Nasal Spray was also recently approved for marketing in Indonesia and the Company is pursuing approval in the Philippines and other markets. Nasodine® Throat Spray is the first follow-on product, and is now available in Singapore and Fiji. Firebrick recently announced plans for a total of up to four products in the Nasodine range and expansion of sales to up to 10 markets over three years. For further information, visit firebrickpharma.com

Contacts:

Media contact:
Matthew Wright, NWR Communications
matt@nwrcommunications.com.au

Shareholder Company contact:
Kam Watson, Firebrick Pharma
investors@firebrickpharma.com

Firebrick Pharma Ltd | ABN 64 157 765 896 | L10, 440 Collins St. Melbourne, VIC, 3000, Australia

P: 1300 301 874 | W: firebrickpharma.com

f